Zitat:"..AVITA Medical Reports Fourth Quarter and Fiscal Year 2021 Financial Results....VALENCIA, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. ....... today reported financial results for its fourth quarter of fiscal year 2021, ended June 30, 2021............Fourth Quarter of Fiscal Year 2021 Highlights................ Total net revenue increased 166% to $10.3 million compared to $3.9 million in the fourth quarter of 2020................... Total commercial revenue increased 45% to $6.7 million compared to the prior quarter ended March 31, 2021 and exceeded revised revenue guidance of $6.0-6.2 million.............................Gross profit margin of 80% compared to 77% in the fourth quarter of 2020.............. Net loss of $4.7 million, or $0.19 per share compared to a net loss of $12.9 million, or $0.60 per share in the fourth quarter of 2020........................... As of June 30, 2021, the Company had $110.7 million in cash and cash equivalents, and no debt FDA approved expanded use of the RECELL® System in combination with meshed autografting for the treatment of all sizes of acute full-thickness thermal burn wounds for both pediatric and adult patients.............Full-Year of Fiscal 2021 Highlights............... Total net revenue increased 105% to $29.2 million compared to $14.3 million in the prior year...................... Commercial revenues increased 50% compared to the prior year....... Gross profit margin of 80% compared to 79% in the prior year Net loss of $26.6 million, or $1.17 per share compared to a net loss of $42.0 million, or $2.07 per share, in the prior year........" ENDE Zitat Quelle:https://www.stockwatch.com/News/Item/U-z8315923-U!RCEL-20210826/U/RCEL |